Cytomegalovirus (CMV) is a common virus most people are exposed to at some point in life, and it's usually harmless with a normal immune system. After a heart transplant, though, the immunosuppression that protects your new heart also allows CMV to reactivate — or, in some cases, to be newly transmitted from the donor organ — and cause real illness. Because of this, essentially every transplant program screens for CMV risk before transplant and follows a specific plan of preventive medication and monitoring afterward. (See Life After Transplant for how this fits into your overall post-transplant care.)
What's Happening: CMV Serostatus and Risk
Before transplant, both you and your donor are tested for prior CMV exposure (an antibody test). That combination defines your personal risk category:
- Donor positive / Recipient negative (D+/R-) — the highest-risk group. The donor heart carries CMV, and because you've never been exposed, you have no baseline immunity to it at all.
- Donor positive or negative / Recipient positive (R+) — intermediate risk. You have prior immunity, but your intentionally suppressed immune system can still allow your own dormant virus to reactivate.
- Donor negative / Recipient negative (D-/R-) — the lowest-risk group, though not zero risk, since CMV can still be acquired later through blood products or ordinary community exposure.
Prevention: Antiviral Prophylaxis
Most transplant programs prescribe a preventive antiviral medication — most often valganciclovir — for a defined period after transplant, timed to your specific risk category: commonly 3–6 months, extended up to 12 months for the highest-risk D+/R- group. This is one part of the broader group of preventive medications taken after transplant. (See Post-Transplant Antimicrobial Prophylaxis for the full picture, including PJP and antifungal prevention alongside CMV.) Some centers instead use a preemptive strategy — close blood monitoring with treatment started only if the virus is actually detected, rather than universal prophylaxis for everyone — your own team will explain which approach they use and why.
Monitoring
Regular blood CMV PCR testing (measuring the actual amount of virus in your blood) is used both during and after the prophylaxis period. This matters even after your antiviral medication ends: the weeks following the end of prophylaxis are actually a higher-risk window for what's called late-onset CMV disease, since your immune system hasn't necessarily developed lasting protection during the period it was being suppressed by the antiviral itself — which is exactly why monitoring continues rather than stopping the moment the medication does.
Symptoms of CMV Disease
- Fever and significant fatigue
- Low blood counts, particularly a drop in white blood cells, often first noticed on routine labs before you feel anything
- GI symptoms — diarrhea, abdominal pain, or GI bleeding if the digestive tract is involved
- Cough or shortness of breath if the lungs are involved (CMV pneumonitis)
- Blurred vision or visual changes, if the retina is involved (CMV retinitis) — this specifically warrants prompt ophthalmology evaluation, not a "wait and see" approach
Treatment
Active CMV disease is treated with antiviral therapy — intravenous ganciclovir for more significant disease, or oral valganciclovir for milder cases — for a treatment course your transplant infectious disease team will define based on how you respond, often confirmed by watching your blood CMV level fall to undetectable. Your team may also temporarily adjust your immunosuppression intensity to help your immune system contribute to clearing the infection, balanced carefully against your ongoing rejection risk — the same kind of clinical balancing act used for any significant post-transplant infection. (See Complications After Transplant.)
Why This Matters Long-Term
Beyond the acute illness itself, CMV infection is independently associated with a higher long-term risk of cardiac allograft vasculopathy — the chronic, diffuse narrowing of the transplanted heart's blood vessels that's one of the recognized long-term threats to a transplanted heart. This is part of why prevention and prompt treatment matter beyond just how you feel in the moment.
Common Questions
Will I definitely get CMV after transplant?
No — your specific risk depends heavily on your donor/recipient serostatus combination, and prevention meaningfully reduces the risk within any category.
Why do I need blood tests for this even after finishing my antiviral medication?
Because the period right after prophylaxis ends is actually a higher-risk window for late-onset CMV disease — monitoring continues specifically to catch this.
Is CMV the same as the flu or a cold?
No — it's a different virus entirely (a type of herpesvirus), and while it's usually mild or silent in people with normal immune function, it behaves very differently under transplant-level immunosuppression.
Can CMV affect my new heart directly?
It can contribute to long-term vessel changes in the transplanted heart (cardiac allograft vasculopathy) independent of causing acute symptoms, which is one more reason your team takes prevention and monitoring seriously even when you feel completely well.